LVIS Stent Versus Enterprise Stent for the Treatment of Unruptured Intracranial Aneurysms

Abstract

This retrospective study compared clinical and angiographic outcomes between LVIS and Enterprise stents. From November 2014 to December 2015, total 190 patients with 208 unruptured intracranial aneurysms were coiled assisted by LVIS andEnterprise stents. Procedure-related complications, clinical outcomes, and angiographic results were analyzed retrospectively. A total of 92 patients with 96 aneurysms received LVIS stents and 98 patients with 112 aneurysms were treated with Enterprise stents. Procedure-related complications occurred in 10.9% of patients (2 hemorrhagic events and 8 thromboembolic events) in the LVIS stents group whereas 16.3% (1 hemorrhage, 1 mass effect, and 14 thromboembolic events) in the Enterprise stents group. No statistical significant differences in thromboembolic (P= 0.263), hemorrhagic complications (P =0.611), and favorable clinical outcomes (modified Rankin Scores of 0-2) (P= 0.379) were found between 2 groups. A greater initial complete or near-complete obliteration wasfound in the LVIS stents group compared with the Enterprise stents group (96.9% vs. 88.4%, P= 0.034). Larger aneurysm size (P= 0.048) was an independent predictor of procedure-related complications in univariate analysis. Compared with Enterprise stents, LVIS stents may achieve greater complete or near-complete occlusion rate. There was no significant difference in procedural-related complications and clinical outcomes between LVIS and Enterprise stents.